Page last updated: 2024-12-07

diacetyldichlorofluorescein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

diacetyldichlorofluorescein: stable storage form of dichlorofluorescein [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID104913
SCHEMBL ID1024927
MeSH IDM0094267

Synonyms (35)

Synonym
dcfda
diacetyldichlorofluorescein
leuco-dcf diacetate
2044-85-1
leukodiacetyl-2,7-dichlorofluorescein
dcfh-da
2',7'-dichlorofluorescein diacetate
2',7'-dichlorofluorescein diacetate, bioreagent, suitable for fluorescence, >=95% (hplc)
(6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate
3',6'-bis(acetyloxy)-2',7'-dichlorospiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one
spiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one, 3',6'-bis(acetyloxy)-2',7'-dichloro-
2 inverted exclamation marka,7 inverted exclamation marka-dichlorofluorescein diacetate
AKOS015903461
SCHEMBL1024927
AC-33584
DTXSID30174389
mfcd00037501
dcfd
2',7'-dichlorofluorescein 3',6'-diacetate
J-013330
2',7'-dichloro-3-oxo-3h-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl diacetate
FT-0739941
spiro[isobenzofuran-1(3h),9'-[9h]xanthen]-3-one, 3',6'-bis(acetyloxy)-2',7'-dichloro-
DS-11315
(6'-acetoxy-2',7'-dichloro-3-oxo-spiro[isobenzofuran-1,9'-xanthene]-3'-yl) acetate
Q26840962
VQVUBYASAICPFU-UHFFFAOYSA-N
2',7'-dichloro-3-oxo-3h-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyldiacetate
D95889
diacetyldichlorofluoresceindcfh-da
2,7-dichlorofluorescindiacetate
A879613
HY-126793
CS-0107435
PD053828

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The genotoxicity of benzoquinone (BQ), a toxic benzene metabolite, is greatly enhanced by the presence of fetal calf serum (FCS) in the incubation medium."( Involvement of oxygen free radicals in the serum-mediated increase of benzoquinone genotoxicity.
De Bartolomeo, A; Fabiani, R; Morozzi, G, 2005
)
0.33
" Results of the present work exclude peroxynitrite involvement in cytokine toxicity to β-cells because its generation did not correlate with the toxic action of cytokines."( Cytokine toxicity in insulin-producing cells is mediated by nitro-oxidative stress-induced hydroxyl radical formation in mitochondria.
Gurgul-Convey, E; Lenzen, S; Lortz, S; Mehmeti, I, 2011
)
0.37
" Based on the results, the four essential oils are considered safe for human consumption at low concentrations."( Evaluation of toxicity of essential oils palmarosa, citronella, lemongrass and vetiver in human lymphocytes.
Ghosh, M; Jothiramajayam, M; Mukherjee, A; Sinha, S, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" The bioavailability and efficacy of antioxidants in human corneal limbal epithelial (HCLE) cells were measured to determine whether antioxidants might be beneficial constituents of lubricant eye drops."( Bioavailability of antioxidants applied to stratified human corneal epithelial cells.
Koetje, LR; Mitchell, AK; Schotanus, MP; Stoddard, AR; Ubels, JL, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" A dose-response of AFB1 was also observed within the range of 10 nM to 1000 nM."( Detection of elevated reactive oxygen species level in cultured rat hepatocytes treated with aflatoxin B1.
Ong, CN; Shen, HM; Shen, Y; Shi, CY, 1996
)
0.29
" In these cells at low dosage (from 1 to 6 microg/ml of medium) ET-18-OCH(3) stimulates maturation and protective responses, whereas at increasing dosages (from 8 to 20 microg/ml) it shows cytotoxic effects."( ET-18-OCH(3)-induced cytotoxicity and DNA damage in rat astrocytes.
Cardile, V; Palumbo, M; Renis, M; Russo, A, 2000
)
0.31
" After dosed for 24 h and 72 h, the NO release of low dose groups were higher than those of the controls, while the NO release of high dose groups showed a downward trend when compared with the control's."( [Effects of atrazine on function of murine peritoneal macrophages in vitro].
Chen, J; Ma, S; Zhang, L, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (421)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (2.14)18.7374
1990's88 (20.90)18.2507
2000's162 (38.48)29.6817
2010's146 (34.68)24.3611
2020's16 (3.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.50 (24.57)
Research Supply Index6.07 (2.92)
Research Growth Index5.57 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.23%)5.53%
Reviews2 (0.47%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other426 (99.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]